Oligonucleotide-based gene targeting technologies

被引:0
|
作者
Filareto, A
Del Vecchio, F
Spitalieri, P
Sangiuolo, F
Brunetti, E
Novelli, G
机构
[1] Univ Roma Tor Vergata, Dipartimento Biopatol & Imaging Diagnost, I-00133 Rome, Italy
[2] Fatebenefratelli Hosp, Rome, Italy
[3] Univ Arkansas Med Sci, Dept Med, Div Cardiovasc Med, Little Rock, AR 72205 USA
关键词
oligonucleotides; targeting technologies; gene transfer;
D O I
暂无
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The major impact of the human genome sequence is the understanding of disease aetiology with deduced therapy. The completion of this project has shifted the interest from the sequencing and identification of genes to the exploration of gene function, signalling the beginning of the postgenomic era. The goal of all gene therapy protocols is to repair the precise genetic defect without additional modification of the genome. It should involve a lasting and tissue specific expression of the functional gene. Besides, in gene therapy preferably any technology used should fulfil several requirements including safety, simplicity of use, cost effectiveness and amenability to industrial scale. The oligonucleotide-base gene targeting strategies now in use are based on the naturally occurred mechanism of homologous recombination (HR). Simply stated, the process involves targeting the mutation in situ for gene correction and for restoration of a normal gene function. HR in eukaryotes is less efficient than in prokaryotic system. Anyway recent advances in gene targeting and novel strategies have led to the suggestion that gene correction based on HR might be used as clinical therapy for genetic disease and used in the cellular genetic therapy approach. Cellular genetic therapy is the ultimate frontier for those pathologies that are the consequent to a specific non-functional cellular type, by the replacement of sick cells with healthy ones, obtained from the same patient or a different donor and previously cured with gene therapy techniques. The purpose of this paper is to review the oligonucleotides based gene targeting technologies: the small fragment homologous recombination (SFHR), the chimeric RNA/DNA oligonucleotides (RDO), triplex forming oligonucleotide (TFO) and the homologous recombination dependent gene targeting (hrdGT). With reference to the naked DNA approach, the recent;availability of better delivery methods (e.g. electroporation and microinjection) has made the non-viral gene transfer an increasingly more important and viable method for gene therapy.
引用
收藏
页码:65 / 76
页数:12
相关论文
共 50 条
  • [21] Delivery of oligonucleotide-based therapeutics: challenges and opportunities
    Hammond, Suzan M.
    Aartsma-Rus, Annemieke
    Alves, Sandra
    Borgos, Sven E.
    Buijsen, Ronald A. M.
    Collin, Rob W. J.
    Covello, Giuseppina
    Denti, Michela A.
    Desviat, Lourdes R.
    Echevarria, Lucia
    Foged, Camilla
    Gaina, Gisela
    Garanto, Alejandro
    Goyenvalle, Aurelie T.
    Guzowska, Magdalena
    Holodnuka, Irina
    Jones, David R.
    Krause, Sabine
    Lehto, Taavi
    Montolio, Marisol
    Van Roon-Mom, Willeke
    Arechavala-Gomeza, Virginia
    EMBO MOLECULAR MEDICINE, 2021, 13 (04)
  • [22] OLIGONUCLEOTIDE-BASED CORRECTION OF CF SPLICING MUTATIONS
    Dang, Y. L.
    van Heusden, C.
    O'Kelly-Nickerson, V
    Randell, S.
    Boucher, R.
    Juliano, R.
    Kreda, S. M.
    PEDIATRIC PULMONOLOGY, 2020, 55 : S201 - S201
  • [23] Current Status of Oligonucleotide-Based Protein Degraders
    Shih, Po-Chang
    Naganuma, Miyako
    Demizu, Yosuke
    Naito, Mikihiko
    PHARMACEUTICS, 2023, 15 (03)
  • [24] Oligonucleotide-Based Therapies for Inflammatory Bowel Disease
    Bevivino, Gerolamo
    Sedda, Silvia
    Marafini, Irene
    Monteleone, Giovanni
    BIODRUGS, 2018, 32 (04) : 331 - 338
  • [25] Oligonucleotide-Based Therapies for Inflammatory Bowel Disease
    Gerolamo Bevivino
    Silvia Sedda
    Irene Marafini
    Giovanni Monteleone
    BioDrugs, 2018, 32 : 331 - 338
  • [26] Targeting RNA editing of antizyme inhibitor 1: A potential oligonucleotide-based antisense therapy for cancer
    Tay, Daryl Jin Tai
    Song, Yangyang
    Peng, Boya
    Toh, Tan Boon
    Hooi, Lissa
    Toh, Desiree-Faye Kaixin
    Hong, HuiQi
    Tang, Sze Jing
    Han, Jian
    Gan, Wei Liang
    Chan, Tim Hon Man
    Krishna, Manchugondanahalli S.
    Patil, Kiran M.
    Maraswami, Manikantha
    Loh, Teck Peng
    Dan, Yock Young
    Zhou, Lei
    Bonney, Glenn Kunnath
    Chow, Pierce Kah-Hoe
    Chen, Gang
    Chow, Edward Kai-Hua
    Le, Minh T. N.
    Chen, Leilei
    MOLECULAR THERAPY, 2021, 29 (11) : 3258 - 3273
  • [27] Antisense Oligonucleotide-Based Therapy of Viral Infections
    Tarn, Woan-Yuh
    Cheng, Yun
    Ko, Shih-Han
    Huang, Li-Min
    PHARMACEUTICS, 2021, 13 (12)
  • [28] Oligonucleotide-based theranostic nanoparticles in cancer therapy
    Shahbazi, Reza
    Ozpolat, Bulent
    Ulubayram, Kezban
    NANOMEDICINE, 2016, 11 (10) : 1287 - 1308
  • [29] Human and mouse oligonucleotide-based array CGH
    van den IJssel, P
    Tijssen, M
    Chin, SF
    Eijk, P
    Carvalho, B
    Hopmans, E
    Holstege, H
    Bangarusamy, DK
    Jonkers, J
    Meijer, GA
    Caldas, C
    Ylstra, B
    NUCLEIC ACIDS RESEARCH, 2005, 33 (22) : e192
  • [30] Oligonucleotide-Based Luminescent Detection of Metal Ions
    Ma, Dik-Lung
    Chan, Daniel Shiu-Hin
    Man, Bradley Yat-Wah
    Leung, Chung-Hang
    CHEMISTRY-AN ASIAN JOURNAL, 2011, 6 (04) : 986 - 1003